Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR001026)
Formula Reactant Fesoterodine 5-hydroxymethyl tolterodine Product Fesoterodine carboxy metabolite
Reactant Info Product Info
Metabolic Enzyme Cytochrome P450 3A4 (CYP3A4) DME Info
Cytochrome P450 2D6 (CYP2D6) DME Info
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR001027 Fesoterodine Fesoterodine 5-hydroxymethyl tolterodine Hydrolysis - Hydrolysis Fesoterodine [1], [2], [3]
MR006782 Tolterodine tartrate 5-Hydroxymethyl tolterodine Oxidation - Methyl-hydroxylation Tolterodine tartrate [4]
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR006783 5-Hydroxymethyl tolterodine 5-Carboxylic acid tolterodine Unclear Tolterodine tartrate [4]
MR006784 5-Hydroxymethyl tolterodine N-Dealkylated 5-hydroxymethyl tolterodine Unclear Tolterodine tartrate [4]
References
1 Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron J Clin Pharmacol. 2019 Nov;59(11):1505-1518. doi: 10.1002/jcph.1438.
2 Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients?with Neurogenic Detrusor Overactivity. Eur J Drug Metab Pharmacokinet. 2023 May;48(3):257-269. doi: 10.1007/s13318-023-00818-8.
3 Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study. J Pediatr Urol. 2023 Apr;19(2):175.e1-175.e10. doi: 10.1016/j.jpurol.2022.11.020.
4 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.